Nanowire Nano-Vaccine Drives Balanced Immune Response and Prophylactic Tumor Protection in Mice

A vaccine platform built from poly-L-lactic acid and zinc oxide nanowires has shown the ability to raise both arms of adaptive immunity against a tumor antigen and to protect mice prophylactically against tumor growth, according to a study published in Cancer Nanotechnology on 17 September 2026. The work, led by Prashant Sharma, Bum Chul Park, Jae-Won Lee, Young Keun Kim and Nam-Hyuk Cho, extends the team’s earlier demonstration of therapeutic effects to the preventive setting, where the vaccine had not previously been tested.

The platform, known as PLLA-ZnO/CEA, consists of carcinoembryonic antigen (CEA) coated onto poly-L-lactic acid–zinc oxide nanocomposites. CEA is a tumor-associated antigen, and the researchers’ earlier work had shown that the nanocomposites could induce strong cellular immunity with therapeutic antitumor effects. What remained unexplored, the authors note, was the humoral immune response — the antibody arm of immunity — and whether the formulation could prevent tumors from taking hold in the first place.

To address both questions, the team immunized female C57BL/6 mice, six animals per group, subcutaneously with the CEA-coated nanocomposites at two-week intervals. Serum antibody responses were measured by ELISA at days 14 and 28 after immunization, with particular attention to two antibody subclasses, IgG1 and IgG2c, which serve as markers of Th2- and Th1-type immunity respectively. Flow cytometry was used to assess IFNγ-producing T cells, and intracellular cytokine staining quantified TNF-α, IL-2 and IFN-γ in splenocytes of tumor-bearing mice. A multi-parameter flow cytometry panel profiled lymphoid cells to characterize immune remodeling in the spleen and the tumor microenvironment.

The antibody results pointed to a notably balanced response. After the second immunization, both IgG1 and IgG2c reached high levels, with optical densities at 450 nanometers of approximately 1.10 and 1.55 respectively. The IgG1/IgG2c ratio for the nano-vaccine was 0.72, which the authors interpret as balanced Th1/Th2 immunity. By contrast, the traditional Alum adjuvant showed a ratio of 1.33, indicating a Th2 bias, and PLLA-ZnO/CEA elicited significantly higher IgG2c responses than Alum at day 28 — 1.55 versus 1.05 OD450, a difference the authors report as statistically significant at p < 0.001.

Beyond antibodies, the in vitro studies confirmed substantial Type I interferon production and migration of CCR7-positive dendritic cells, processes relevant to how a vaccine recruits and activates immune cells. Flow cytometry demonstrated robust IFNγ-positive CD4-positive and CD8-positive T cell responses upon antigen restimulation, indicating that the cellular arm of immunity was also engaged.

The prophylactic test used a tumor challenge model in which mice were vaccinated and then challenged with MC38/CEA cells. In this model, vaccination with PLLA-ZnO/CEA significantly reduced tumor growth by 65 to 70 percent compared with PBS controls, a difference reported at p < 0.001, with sustained protection throughout the observation period. The authors emphasize that this protection was sustained, not transient, over the period the animals were followed.

Examination of vaccinated tumor-bearing mice revealed what the researchers describe as active immune remodeling. The animals exhibited robust antigen-specific polyfunctional T-cell responses, with TNF-α, IL-2 and IFN-γ produced by both CD4-positive and CD8-positive splenocytes, alongside significant expansion of splenic CD8-positive T cells and tumor-infiltrating NK cells.

Taken together with the characterization of CEA antigen immobilization and dendritic cell uptake, the authors conclude that the CEA-coated PLLA-ZnO nanocomposites elicit balanced Th1/Th2 humoral immunity alongside robust cellular responses, providing significant prophylactic protection against tumor growth. They position the platform as a versatile, mechanistically characterized vaccine system that they argue is superior to traditional adjuvants for both preventive and therapeutic cancer immunotherapy.

It is worth noting the scope of these findings. The results come from a mouse model using MC38/CEA tumor cells, with six animals per group, and the article is being shared early as a peer-reviewed, accepted version that is subject to further edits before the final Version of Record. The prophylactic protection demonstrated here applies to the tumor challenge setting in mice and does not by itself establish efficacy in humans. Nevertheless, the study adds a preventive dimension to a platform previously shown only to have therapeutic effects, and it provides a detailed immunological picture — antibody subclasses, polyfunctional T cells, dendritic cell migration and immune remodeling in the tumor microenvironment — of how the nanowire-based formulation achieves that balance.

Subject of Research: A CEA-coated PLLA–ZnO nanowire nano-vaccine that induces balanced Th1/Th2 immunity and prophylactic antitumor protection in mice

Article Title: PLLA–ZnO nanowire nano-vaccine orchestrates balanced Th1/Th2 immunity and confers prophylactic antitumor protection

Article References: Sharma, P., Park, B. C., Lee, J.-W., Kim, Y. K., & Cho, N.-H. (2026). PLLA–ZnO nanowire nano-vaccine orchestrates balanced Th1/Th2 immunity and confers prophylactic antitumor protection. Cancer Nanotechnology. https://doi.org/10.1186/s12645-026-00429-3

Image Credits: AI Generated

DOI: 10.1186/s12645-026-00429-3

Keywords: PLLA-ZnO nanocomposites, nano-vaccine, carcinoembryonic antigen, Th1/Th2 immunity, IgG2c, prophylactic antitumor immunity, MC38/CEA tumor model, dendritic cell migration, polyfunctional T cells, Cancer Nanotechnology, zinc oxide nanowires, cancer immunotherapy